TY - JOUR
T1 - Nationwide Laboratory Surveillance of Progressive Multifocal Leukoencephalopathy in Japan
T2 - Fiscal Years 2011–2020
AU - Nakamichi, Kazuo
AU - Miura, Yoshiharu
AU - Shimokawa, Toshio
AU - Takahashi, Kenta
AU - Suzuki, Tadaki
AU - Funata, Nobuaki
AU - Harada, Masafumi
AU - Mori, Koichiro
AU - Sanjo, Nobuo
AU - Yukitake, Motohiro
AU - Takahashi, Kazuya
AU - Hamaguchi, Tsuyoshi
AU - Izaki, Shoko
AU - Oji, Satoru
AU - Nakahara, Jin
AU - Ae, Ryusuke
AU - Kosami, Koki
AU - Nukuzuma, Souichi
AU - Nakamura, Yosikazu
AU - Nomura, Kyoichi
AU - Kishida, Shuji
AU - Mizusawa, Hidehiro
AU - Yamada, Masahito
AU - Takao, Masaki
AU - Ebihara, Hideki
AU - Saijo, Masayuki
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/4
Y1 - 2023/4
N2 - Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease caused by JC virus (JCV), predominantly affecting patients with impaired cellular immunity. PML is a non-reportable disease with a few exceptions, making national surveillance difficult. In Japan, polymerase chain reaction (PCR) testing for JCV in the cerebrospinal fluid (CSF) is performed at the National Institute of Infectious Diseases to support PML diagnosis. To clarify the overall profile of PML in Japan, patient data provided at the time of CSF-JCV testing over 10 years (FY2011–2020) were analyzed. PCR testing for 1537 new suspected PML cases was conducted, and 288 (18.7%) patients tested positive for CSF-JCV. An analysis of the clinical information on all individuals tested revealed characteristics of PML cases, including the geographic distribution, age and sex patterns, and CSF-JCV-positivity rates among the study subjects for each type of underlying condition. During the last five years of the study period, a surveillance system utilizing ultrasensitive PCR testing and widespread clinical attention to PML led to the detection of CSF-JCV in the earlier stages of the disease. The results of this study will provide valuable information not only for PML diagnosis, but also for the treatment of PML-predisposing conditions.
AB - Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease caused by JC virus (JCV), predominantly affecting patients with impaired cellular immunity. PML is a non-reportable disease with a few exceptions, making national surveillance difficult. In Japan, polymerase chain reaction (PCR) testing for JCV in the cerebrospinal fluid (CSF) is performed at the National Institute of Infectious Diseases to support PML diagnosis. To clarify the overall profile of PML in Japan, patient data provided at the time of CSF-JCV testing over 10 years (FY2011–2020) were analyzed. PCR testing for 1537 new suspected PML cases was conducted, and 288 (18.7%) patients tested positive for CSF-JCV. An analysis of the clinical information on all individuals tested revealed characteristics of PML cases, including the geographic distribution, age and sex patterns, and CSF-JCV-positivity rates among the study subjects for each type of underlying condition. During the last five years of the study period, a surveillance system utilizing ultrasensitive PCR testing and widespread clinical attention to PML led to the detection of CSF-JCV in the earlier stages of the disease. The results of this study will provide valuable information not only for PML diagnosis, but also for the treatment of PML-predisposing conditions.
KW - JC virus
KW - cerebrospinal fluid
KW - laboratory surveillance
KW - progressive multifocal leukoencephalopathy
KW - real-time PCR testing
UR - https://www.scopus.com/pages/publications/85156253565
UR - https://www.scopus.com/pages/publications/85156253565#tab=citedBy
U2 - 10.3390/v15040968
DO - 10.3390/v15040968
M3 - Article
C2 - 37112948
AN - SCOPUS:85156253565
SN - 1999-4915
VL - 15
JO - Viruses
JF - Viruses
IS - 4
M1 - 968
ER -